General Information of Drug (ID: DMDK4MG)

Drug Name
M7583 Drug Info
Synonyms
ZAXMFSSGOARPBM-UHFFFAOYSA-N; 51123-09-2; 5-amino-n-ethyl-2-methyl-n-phenylbenzenesulfonamide; 5-Amino-N-ethyl-2-methyl-N-phenylbenzenesulphonamide; 4-AMINO TOLUENE-2-(N-ETHYL) SULFONANILIDE; 5-AMINO-N-ETHYL-O-TOLUENESULFONANILIDE; Q-200530; AMINO-4-METHYL-BENZENE-3-(N-ETHYL)-SULFANILIDE; 5-amino-N-ethyl-2-methyl-N-phenylbenzene-1-sulfonamide; NSC84161; EINECS 256-998-5; NSC 84161; AC1Q2YPH; AC1L3WX0; AC1Q6V7C; AC1Q2YP6; SCHEMBL9072675; 4-Aminotoluol-2-sulfethylanilid; Benzenesulfonamide, 3-amino-N-ethyl-6-methyl-N-phenyl-; CTK4J3696; MolPort-001-759-851
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1 [1]
Cross-matching ID
PubChem CID
96649
CAS Number
CAS 51123-09-2
TTD Drug ID
DMDK4MG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibrutinib DMHZCPO Mantle cell lymphoma 2A85.5 Approved [2]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [3]
Zanubrutinib DMJWRQP Mantle cell lymphoma 2A85.5 Approved [4]
Pirtobrutinib DMRG1X3 Non-hodgkin lymphoma 2B33.5 Approved [5]
GDC-0853 DMBEL3Q Multiple sclerosis 8A40 Phase 3 [6]
ICP-022 DMU72KL Chronic lymphocytic leukaemia 2A82.0 Phase 3 [7]
Tolebrutinib DML19V6 Multiple sclerosis 8A40 Phase 3 [8]
CC-292 DMJR9H0 Chronic lymphocytic leukaemia 2A82.0 Phase 2 [9]
BMS-986142 DMZB8AJ Rheumatoid arthritis FA20 Phase 2 [6]
LOU064 DME8O5K Chronic idiopathic urticaria EB00.1 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of InnoCare Pharma.
8 Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
9 Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)